Cetera Advisors LLC Vaxart, Inc. Transaction History

Cetera Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$0.56 - $1.41 $2,741 - $6,901	-4,895 Reduced 26.46%	13,605 $17,000
Q3 2023 Nov 14, 2023	SELL	$0.69 - $0.85 $4,623 - $5,695	-6,700 Reduced 26.59%	18,500 $13,000
Q2 2023 Aug 09, 2023	SELL	$0.6 - $1.41 $6,720 - $15,792	-11,200 Reduced 30.77%	25,200 $18,000
Q1 2023 May 15, 2023	SELL	$0.71 - $1.25 $4,721 - $8,312	-6,650 Reduced 15.45%	36,400 $27,000
Q4 2022 Feb 14, 2023	SELL	$0.75 - $2.24 $9,750 - $29,120	-13,000 Reduced 23.19%	43,050 $41,000
Q3 2022 Nov 10, 2022	SELL	$2.09 - $4.5 $87,100 - $187,537	-41,675 Reduced 42.65%	56,050 $122,000
Q2 2022 Aug 11, 2022	SELL	$2.7 - $5.28 $21,060 - $41,184	-7,800 Reduced 7.39%	97,725 $342,000
Q1 2022 May 12, 2022	BUY	$4.29 - $6.64 $452,702 - $700,686	105,525 New	105,525 $532,000

107

37.7M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $86M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisors LLC with notifications on news.